Literature DB >> 15705634

Wnt signalling in rheumatoid arthritis.

M Sen1.   

Abstract

Rheumatoid arthritis (RA) is a symmetrical polyarticular disease of unknown aetiology that affects primarily the diarthrodial joints. Characteristic features of RA pathogenesis are synovial hyperplasia and inflammation accompanied by cartilage loss and joint destruction. Synovial hyperplasia and inflammation are a consequence of an increase in the macrophage-like and fibroblast-like synoviocytes of the synovial intimal lining associated with infiltration of leucocytes into the subintimal space. Although therapeutic interventions are available, the disease persists despite therapy in a significant fraction of patients. Several lines of evidence have substantiated a crucial role of activated fibroblast-like synoviocytes (FLS) during RA pathogenesis. The hyperplastic FLS population potentially promotes leucocyte infiltration and retention. The rheumatoid synovium eventually transforms into a pannus that destroys articular cartilage and bone. There are no approved drugs that are known to target the FLS in RA, and the underlying mechanisms driving FLS activation remain unresolved. In this review, the importance of Wnt-frizzled (Fz)-mediated signalling in the autonomous activation of FLS is discussed. Anti-Wnt/anti-Fz antibodies, Fz receptor antagonists or small-molecule inhibitors of Wnt-Fz signalling might be useful for therapeutic interventions in refractory RA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705634     DOI: 10.1093/rheumatology/keh553

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  25 in total

1.  Leptin receptor JAK2/STAT3 signaling modulates expression of Frizzled receptors in articular chondrocytes.

Authors:  S Ohba; T M Lanigan; B J Roessler
Journal:  Osteoarthritis Cartilage       Date:  2010-09-22       Impact factor: 6.576

2.  In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.

Authors:  Angelo Fassio; Luca Idolazzi; Ombretta Viapiana; Camilla Benini; Elisabetta Vantaggiato; Francesco Bertoldo; Maurizio Rossini; Davide Gatti
Journal:  Clin Rheumatol       Date:  2017-06-20       Impact factor: 2.980

3.  Genomic loci and candidate genes underlying inflammatory nociception.

Authors:  Harsha K Nair; Heather Hain; Raymond M Quock; Vivek M Philip; Elissa J Chesler; John K Belknap; William R Lariviere
Journal:  Pain       Date:  2010-12-30       Impact factor: 6.961

4.  The Wingless homolog Wnt5a stimulates phagocytosis but not bacterial killing.

Authors:  George Maiti; Debdut Naskar; Malini Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

5.  TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness.

Authors:  Stephanie M Stanford; German R Aleman Muench; Beatrix Bartok; Cristiano Sacchetti; William B Kiosses; Jay Sharma; Michael F Maestre; Massimo Bottini; Tomas Mustelin; David L Boyle; Gary S Firestein; Nunzio Bottini
Journal:  Ann Rheum Dis       Date:  2014-11-06       Impact factor: 19.103

6.  Immunoexpression of canonical Wnt and NF-κB signaling pathways in the temporomandibular joint of arthritic rats.

Authors:  Luane Macêdo de Sousa; Joana Maria Dos Santos Alves; Conceição da Silva Martins; Karuza Maria Alves Pereira; Paula Goes; Delane Viana Gondim
Journal:  Inflamm Res       Date:  2019-08-01       Impact factor: 4.575

7.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

Review 8.  The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.

Authors:  Sinyi Kong; Pricilla Yeung; Deyu Fang
Journal:  J Genet Genomics       Date:  2013-04-12       Impact factor: 4.275

9.  Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models.

Authors:  Ying Chen; Yang Hu; Ti Zhou; Kevin K Zhou; Robert Mott; Mingyuan Wu; Michael Boulton; Timothy J Lyons; Guoquan Gao; Jian-xing Ma
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

10.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authors:  Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine Mitsiades; Rao Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.